Huntington data quell fears about Wave's platform, but leave plenty to prove

The latest data from Wave allayed some doubts about the company’s stereopure oligonucleotide platform, but suggested that the biotech has yet to prove it can generate a competitive product. The company plans to double the top dose of Huntington disease therapy WVE-120102 after efficacy measurements fell short of those seen from a competing program.

Shareholders continued to punish the company's stock Monday, with shares dipping $7.82 (49%) to $7.99; Wave Life Sciences Ltd. (NASDAQ:WVE) has lost more than three quarters of its value this month...